A Phase 2/3 Open Label Randomized Study of Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Subjects With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer After Progression on a Third-Generation EGFR TKI - AndroMETa-Lung-713
A Phase 2/3 Open Label Randomized Study of Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Subjects With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer After Progression on a Third-Generation EGFR TKI - AndroMETa-Lung-713
Non-small cell lung cancer (NSCLC) is a common type of lung cancer where abnormal cells in the lungs grow out of control. The purpose of this study is to assess adverse events and change in disease activity of telisotuzumab adizutecan as a monotherapy or in combination with osimertinib compared to standard of care (SOC).
Telisotuzumab adizutecan is an investigational drug being developed for the treatment of NSCLC. This study will be divided into two stages, in the first stage (phase 2) participants will receive 1 of 2 doses of telisotuzumab adizutecan as a monotherapy or in combination with osimertinib. In the second stage (phase 3) participants will receive the recommended phase 3 dose (RP3D) of telisotuzumab adizutecan, from the previous stage, or SOC. Approximately 490 adult participants with NSCLC will be enrolled in the study in 200 sites around the world.
In phase 2, participants will receive 1 of 2 intravenous (IV) doses of telisotuzumab adizutecan as a monotherapy or in combination with oral osimertinib. In phase 3, participants will receive the IV RP3D of telisotuzumab adizutecan, or SOC. The study will run for a duration of approximately 69 months.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects.
Inclusion Criteria:
Exclusion Criteria:
abbvieclinicaltrials@abbvie.com844-663-3742
Springdale, Arkansas 72762, United States
479-872-8130
Irvine, California 92618, United States
Rockledge, Florida 32955, United States
Saint Louis Park, Minnesota 55426, United States
Knoxville, Tennessee 37909, United States
Vancouver, Washington 98684, United States
Nanchang, Jiangxi 330209, China
Ürümqi, Xinjiang 830000, China
Fano, Pesaro E Urbino 61032, Italy
Rome, Roma 00144, Italy
Candiolo, Torino 10060, Italy
Verona, 37126, Italy
Sagamihara-shi, Kanagawa 252-0375, Japan
Chuo-Ku, Tokyo 104-0045, Japan
Poznan, Greater Poland Voivodeship 60-569, Poland
Guimarães, Braga District 4835-044, Portugal
Loures, Lisbon District 2674-514, Portugal
Senhora da Hora, Porto District 4464-513, Portugal
Kamenitz, Sremski Okrug 21208, Serbia
Kragujevac, Sumadijski Okrug 34000, Serbia
Cheongju-si, North Chungcheong 28644, South Korea
Seoul, Seoul Teugbyeolsi 03722, South Korea
Santiago de Compostela, A Coruna 15706, Spain
Kaohsiung City, 807, Taiwan
Adapazarı, Sakarya 54290, Turkey (Türkiye)
Ankara, 06620, Turkey (Türkiye)
Istanbul, 34722, Turkey (Türkiye)
Istanbul, 34899, Turkey (Türkiye)
London, Greater London EC1A 7BE, United Kingdom